This review demonstrated the increased expression of HMGB-1 in thrombosis-related diseases, including coronary artery disease, stroke, peripheral arterial disease, disseminated intravascular coagulation, and venous thrombosis.
Previous studies have shown that long-term administration of SBP (1-2 pills three times daily, for at least 6 months) for treatment of CAD is effective and safe, with a significant, long-term effect.
HMGB1 and its 3 well-known receptors, receptor for advanced glycation end products, Toll-like receptor 2 (TLR2), and TLR4, were examined by immunohistochemistry on myocardial biopsy specimens from 18 elderly patients with CAD (10 with IRD, 8 without IRD).
We observed other cCIMT-LEA regions associated with other clinical events, most notably the regions harboring <i>CKMT2</i> gene (creatine kinase, mitochondrial 2) and <i>RASGRF2</i> gene (Ras protein-specific guanine nucleotide-releasing factor 2) with all clinical events except stroke, the <i>LRRC3B</i> gene (leucine-rich repeat containing 3B) with myocardial infarction, the <i>PRMT3</i> gene (protein arginine methyltransferase 3) with stroke, and the <i>LHFPL2</i> gene (lipoma high mobility group protein I-C fusion partner-like 2) with hard and all coronary heart disease.
The role of high mobility group box 1 (HMGB1) has been demonstrated in stroke and coronary artery disease but not in peripheral arterial occlusive disease (PAOD).